Pharma Neuigkeiten
(von Worldpharmanews)
Helpful Articles
Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
Amgen (NASDAQ:AMGN) announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study...
Merck total revenues increase 3.2% to € 2.6 billion
The Merck Group's first-quarter 2012 total revenues rose 3...